Therapy of Crohn’s disease in childhood

Bibliography

• COSGROVE M, AL ATIA RE JENKINS HR: The epidemiology of paediatric inflammatory bowel disease. Arch. Dis. Child. (1996) 74:460–461.
   PubMed Web of Science ®Google Scholar
• SAWCZENKO A, SANDHU BK, LOGAN RF et al.: Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet (2001) 357:1093–1094.
   PubMed Web of Science ®Google Scholar
• LOFTUS EV JR, SCHOENFELD P, SANDBORN WJ: The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Ailment. Pharmacol Ther. (2002) 16:51–60.
   PubMed Web of Science ®Google Scholar
• JOBLING JC, LINDLEY KJ, YOUSEF Y, GORDON I, MILLA PJ: Investigating inflammatory bowel disease - white cell scanning, radiology, and colonoscopy. Arch. Dis. Child (1996) 74:22–26.
   PubMed Web of Science ®Google Scholar
• SHAH DB, COSGROVE M, REES JI, JENKINS HR: The technetium white cell scan as an initial imaging investigation for evaluating suspected childhood inflammatory bowel disease. Pediatr. Gastroenterol Nutr. (1997) 25:524–528.
   PubMed Web of Science ®Google Scholar
• ESCHER JC, TEN-KATE F, LICHTENBELT K et al.: Value of rectosigmoidoscopy with biopsies for diagnosis of inflammatory bowel disease in children. Inflamm. Bowel. Dis. (2002) 8:16–22.
   PubMed Web of Science ®Google Scholar
• BEATTIE RM, WALKER-SMITH JA, MURCH SH: Indications for investigation of chronic gastrointestinal symptoms. Arch. Dis. Child (1995) 73:354–355.
   PubMed Web of Science ®Google Scholar
• LOFTUS EV JR, TREMAINE WJ, HABERMANN TM et al.: Risk of lymphoma in inflammatory bowel disease. Am.j Gastroenterol (2000) 95:2308–2312.
   PubMed Web of Science ®Google Scholar
• OLIVA-HEMKER M, FIOCCHI C: Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm. Bowel. Dis. (2002) 8:112–128.
   PubMed Web of Science ®Google Scholar
• BALLINGER A: Management of growth retardation in the young patient with Crohn's disease. Expert Opin. Pharmacothec (2002) 3:1–7.
   PubMedGoogle Scholar
• BRUCE T: Emotional sequelae of chronic inflammatory bowel disease in children and adolescents. Clin. Gastroenterol (1986) 15:89–104.
   PubMedGoogle Scholar
• SAVAGE MO, BEATTIE RM, CAMACHO-HUBNER C, WALKER- SMITH JA, SANDERSON IR: Growth in Crohn's disease. Acta Paediati: (1999) 88\(Supp0:89–92.
   Google Scholar
• THOMAS AG, TAYLOR F, MILLER V: Dietary intake and nutritional treatment in childhood Crohn's disease. J. Pediatr. Gastroenterol Nutr. (1993) 17:75–81.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS AM, NGUYEN P, SMITH C,MACMILLAN JH, SHERMAN PM: Growth and clinical course of children with Crohn's disease. Gut (1993) 34:939–943.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND H, KARLBERG J, KRISTIANSSON B: Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol Nutr. (1994) 18:165–173.
   PubMed Web of Science ®Google Scholar
• LIPSON AB, SAVAGE MO, DAVIES PS et al.: Acceleration of linear growth following intestinal resection for Crohn disease. Eur.j Pediatr. (1990) 149:687–690.
   PubMed Web of Science ®Google Scholar
• DAVIES G, EVANS CM, SHAND WS, WALKER-SMITH JA: Surgery for Crohn's disease in childhood: influence of site of disease and operative procedure on outcome. Br: J. Surg. (1990) 77:891–894.
   PubMed Web of Science ®Google Scholar
• MURCH SH, LAMKIN VA, SAVAGE MO, WALKER-SMITH JA, MACDONALD TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 32:913–917.
   PubMed Web of Science ®Google Scholar
• THOMAS AG, MILLER V, TAYLOR F et al.: Whole body protein turnover in childhood Crohn's disease. Gut (1992) 33:675–677.
   PubMed Web of Science ®Google Scholar
• THOMAS AG, HOLLY JM, TAYLOR F, MILLER V: Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut (1993) 34:944–947.
   PubMed Web of Science ®Google Scholar
• BEATTIE RM, CAMACHO-HUBNER C, WACHARASINDHU Set al.: Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin. Endocrinol (1998) 49:483–489.
   Google Scholar
• MARKOWITZ J, GRANCHER K, ROSA J, AIGES H, DAUM F: Growth failure in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol Nutr. (1993) 16:373–380.
   PubMed Web of Science ®Google Scholar
• SPRAY C, DEBELLE GD, MURPHY MS: Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatrica (2001) 90:400–405.
   PubMed Web of Science ®Google Scholar
• AXELSSON CJ, ARNUM S: Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand. Gastroenterol (1977) 12:89–95.
   PubMed Web of Science ®Google Scholar
• O'MORAIN C, SEGAL AW, LEVI AJ: Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br. Med. J. (Clin. Res. Ed.) (1984) 288:1859–1862.
   PubMed Web of Science ®Google Scholar
• KIRSCHNER BS, KLICH JR, KALMAN SS, DEFAVARO MV, ROSENBERG IH: Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology (1981) 80:10–15.
   PubMed Web of Science ®Google Scholar
• O'MORAIN C, SEGAL AM, LEVI AJ, VALMAN HB: Elemental diet in acute Crohn's disease. Arch. Dis. Child. (1983) 58:44–47.
   PubMed Web of Science ®Google Scholar
• SANDERSON IR, UDEEN S, DAVIES PS, SAVAGE MO, WALKER-SMITH JA: Remission induced by an elemental diet in small bowel Crohn's disease. Arch. Dis. Child. (1987) 62:123–127.
   PubMed Web of Science ®Google Scholar
• PAPADOPOULOU A, RAWASHDEH MO, BROWN GA, MCNEISH AS, BOOTH IW: Remission following an elemental diet or prednisolone in Crohn's disease. Acta Paediatr. (1995) 84:79–83.
   PubMed Web of Science ®Google Scholar
• BEATTIE RM, SCHIFFRIN EJ, DONNET-HUGHES A et al: Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment. Pharmacol Ther. (1994) 8:609–615.
   PubMed Web of Science ®Google Scholar
• RUUSKA T, SAVILAHTI E, MAKI M, ORMALA T, VISAKORPI JK: Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J. Pediatr. Gastroenterol Nutr. (1994) 19:175–180.
   PubMed Web of Science ®Google Scholar
• FELL JM, PAINTIN M, ARNAUD-BATTANDIER F et al.: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment. Pharmacol Ther. (2000) 14:281–289.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS AM, OHLSSON A, SHERMAN PM, SUTHERLAND LR: Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology (1995) 108:1056–1067.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-BANARES F, CABRE E, ESTEVE-COMAS M, GASSULL MA: How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. Japan J. Parenter: Enter. Nutr. (1995) 19:356–364.
   PubMed Web of Science ®Google Scholar
• WIGHT N, SCOTT BB, WRIGHT N: Dietary treatment of active Crohn's disease. Br. Med. J. (1997) 314:454–455.
   PubMedGoogle Scholar
• ZACHOS M, TONDEUR M, GRIFFITHS AM: Enteral nutritional therapy for inducing remission of Crohn's disease (cochrane review). Cochrane Database Syst. Rev (2001) 3:CD000542.
   Google Scholar
• AKOBENG AK, MILLER V, STANTON J, ELBADRI AM, THOMAS AG: Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. I Pediatr. Gastroenterol Nutr. (2000) 30:78–84.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-BANARES F, CABRE E, GONZALEZ-HUIX F, GASSULL MA: Enteral nutrition as primary therapy in Crohn's disease. Gut (1994) 35:S55–S59.
   Google Scholar
• BEATTIE RIVI, BENTSEN BS, MACDONALD TT: Childhood Crohn's disease and the efficacy of enteral diets. Nutrition (1998) 14:345–350.
   PubMed Web of Science ®Google Scholar
• RIORDAN AM, HUNTER JO, COWAN RE et al.: Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. Lancet (1993) 342:1131–1134.
   PubMed Web of Science ®Google Scholar
• TEAHON K, BJARNASON I, PEARSON M, LEVI AJ: Ten years' experience with an elemental diet in the management of Crohn's disease. Gut (1990) 31:1133–1137.
   PubMed Web of Science ®Google Scholar
• BEATTIE RIVI, WALKER-SMITH JA: Treatment of active Crohn's disease by exclusion diet. J. Pediatr. Gastroenterol Nutr. (1994) 19:135–136.
   PubMedGoogle Scholar
• RIGAUD D, COSNES J, LE QUINTREC Y et al.: Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut (1991) 32:1492–1497.
   Google Scholar
• GORARD DA, HUNT JB, PAYNE-JAMES JJ et al.: Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut (1993) 34:1198–1202.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-HUIX F, DE LEON R, FERNANDEZ-BANARES F et al: Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut (1993) 34:778–782.
   PubMed Web of Science ®Google Scholar
• RANDELL T, MURPHY MS: Evaluation of elemental diet therapy as a long-term strategy for managing Crohn's disease in childhood. Arch. Dis. Child (2002) 84:A4- A4.
   Google Scholar
• BELLI DC, SEIDMAN E, BOUTHILLIER L et al.: Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology (1988) 94:603–610.
   PubMed Web of Science ®Google Scholar
• POLK DB, HATTNER JA, KERNER JAJR: Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease. Japan I. Parenter. Enteral Nutr. (1992) 16:499–504.
   PubMed Web of Science ®Google Scholar
• WILSCHANSKI M, SHERMAN P, PENCHARZ P et al: Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut (1996) 38:543–548.
   PubMed Web of Science ®Google Scholar
• VERMA S, HOLDSWORTH CD, GIAFFER MH: Does adjuvant nutritional support diminish steroid dependency in Crohn's disease? Scand. Gastroenterol (2001) 36:383–388.
   Web of Science ®Google Scholar
• BELLUZZI A, BRIGNOLA C, CAMPIERI M et al.: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl. J. Med. (1996) 334:1557–1560.
   PubMed Web of Science ®Google Scholar
• SALVATORE S, HEUSCHKEL R, TOMLIN S et al.: A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment. Pharmacol Ther. (2000) 14:1567–1579.
   PubMed Web of Science ®Google Scholar
• SHANAHAN F: Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm. Bowel Dis. (2000) 6:107–115.
   PubMed Web of Science ®Google Scholar
• DUNNE C: Adaptation of bacteria to theintestinal niche: probiotics and gut disorder. Inflamm. Bowel. Dis. (2001) 7:136–145.
   PubMed Web of Science ®Google Scholar
• GUPTA P, ANDREW H, KIRSCHNER BS, GUANDALINI S: Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol Nutr. (2000) 31:453–457.
   PubMed Web of Science ®Google Scholar
• COWAN FJ, WARNER IT, DUNSTANFD et al.: Inflammatory bowel disease and predisposition to osteopenia. Arch. Dis. Child. (1997) 76:325–329.
   PubMed Web of Science ®Google Scholar
• HABTEZION A, SILVERBERG MS, PARKES R, MIKOLAINIS S, STEINHART AH: Risk factors for low bone density in Crohn's disease. Inflamm. Bowel. Dis. (2002) 8:87–92.
   PubMed Web of Science ®Google Scholar
• PAPAIOANNOU A, FERKO NC, ADACHI JD: All patients with inflammatory bowel disease should have bone density assessment: pro. Inflamm. Bowel. Dis. (2001) 7:158–162.
   PubMed Web of Science ®Google Scholar
• LESLIE WD: All patients with inflammatory bowel disease should have bone density assessment: con. Inflamm. Bowel. Dis. (2001) 7:163–167.
   PubMed Web of Science ®Google Scholar
• SCHOON EJ, BLOK BM, GEERLING BJ et al.: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology (2000) 119:1203–1208.
   PubMed Web of Science ®Google Scholar
• BOOT AM, BOUQUET J, KRENNING EP, DE MUINCK KEIZER-SCHRAMA SM: Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut (1998) 42:188–194.
   PubMed Web of Science ®Google Scholar
• GOKHALE R, FAVUS MJ, KARRISON T et al.: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology (1998) 114:902–911.
   PubMed Web of Science ®Google Scholar
• MURCH SH, WALKER-SMITH JA: Medical management of chronic inflammatory bowel disease. Baillieres Clin. Gastroenterol (1994) 8:133–148.
   PubMed Web of Science ®Google Scholar
• HEUSCHKEL RB, MENACHE CC, MEGERIAN JT, BAIRD AE: Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. I Pediatr. Gastroenterol Nutr. (2000) 31:8–15.
   PubMed Web of Science ®Google Scholar
• STEINHART AH, EWE K, GRIFFITHS AM, MODIGLIANI R, THOMSEN 00: Corticosteroids for maintaining remission of Crohn's disease (Cochrane Review). Cochrane Database Syst. Rev. (2001) 3:CD000301.
   Google Scholar
• SACHAR DB: Budesonide for inflam-matory bowel disease. It is a magic bullet? N Engl. J. Med. (1994) 331:873–874.
   PubMed Web of Science ®Google Scholar
• BAR-MEIR S, CHOWERS Y, LAVY A et al.: Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology (1998) 115:835–840.
   Google Scholar
• KUNDHAL P, ZACHOS M, HOLMES JL, GRIFFITHS AM: Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. I Pediatr. Gastroenterol Nutr. (2001) 33:75–80.
   PubMed Web of Science ®Google Scholar
• LEVINE A, BROIDE E, STEIN M et al.:Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. I Pediatr. (2002) 140:75–80.
   Google Scholar
• THOMSEN 00, CORTOT A, JEWELL D et al.: A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl. J. Med. (1998) 339:370–374.
   Google Scholar
• MODIGLIANI R, MARY JY, SIMON JFet al.: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflamm-atoires Digestives. Gastroenterology (1990) 98:811–818.
   Google Scholar
• LANDI B, ANH TN, CORTOT A et al.:Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflamm-atoires Digestives. Gastroenterology (1992) 102:1647–1653.
   Google Scholar
• SINGLETON JW, HANAUER SB, GITNICK GL et al.: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 104:1293–1301.
   PubMed Web of Science ®Google Scholar
• FERRY GD: IBD: which 5-ASA drug works where?" Pediatr. Gastroenterol. Nutr. (1993) 16:474–475.
   PubMedGoogle Scholar
• GRIFFITHS A, KOLETZKO S, SYLVESTER F, MARCON M, SHERMAN P: Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. Pediatr. Gastroenterol. Nutr. (1993) 17:186–192.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, GOMOLLON F, MATE J, PAJARES JM: Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig. Dis. Sci. (2002) 47:471–488.
   PubMed Web of Science ®Google Scholar
• JICK H, MYERS MW, DEAN AD: The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy (1995) 15:176–181.
   PubMed Web of Science ®Google Scholar
• GENDRE JP, MARY JY, FLORENT C et al: Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology (1993) 104:435–439.
   Google Scholar
• MAHMUD N, KAMM MA, DUPAS JL et al: Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut (2001) 49:552–556.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND LR, MARTIN F, BAILEY RJ et al.: A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology (1997) 112:1069–1077.
   PubMed Web of Science ®Google Scholar
• CAMMA C, GIUNTA M, ROSSELLI M, COTTONE M: Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology (1997) 113:1465–1473.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC, YANG H, HASSARD PV et al: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 122:904–915.
   PubMed Web of Science ®Google Scholar
• SANDBORN W, SUTHERLAND L, PEARSON D et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev (2000) CD000545.
   Google Scholar
• PEARSON DC, MAY GR, FICK G, SUTHERLAND LR: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev (2000) CD000067.
   Google Scholar
• MARKOWITZ J, GRANCHER K, KOHN N, LESSER M, DAUM F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology (2000) 119:895–902.
   PubMed Web of Science ®Google Scholar
• CASSON DH, DAVIES SE, THOMSON MA et al: Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Ailment. Pharmacol. Ther: (1999) 13:891–895.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, TREMAINE WJ, WOLF DC et al.: Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 117:527–535.
   Google Scholar
• BOUHNIK Y, LEMANN M, MARY JY et al.: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet (1996) 347:215–219.
   PubMed Web of Science ®Google Scholar
• FRASER AG, ORCHARD TR, JEWELL DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut (2002) 50:485–489.
   PubMed Web of Science ®Google Scholar
• CONNELL WR, KAMM MA, DICKSON M et al: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (1994) 343:1249–1252.
   PubMed Web of Science ®Google Scholar
• LEWIS JD, SCHWARTZ JS, LICHTENSTEIN GR: Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology (2000) 118:1018–1024.
   PubMed Web of Science ®Google Scholar
• MACK DR, YOUNG R, KAUFMAN SS, RAMEY L, VANDERHOOF JA: Methotrexate in patients with Crohn's disease after 6-mercaptopurine. Pediatr. (1998) 132:830–835.
   Web of Science ®Google Scholar
• CHONG RY, HANAUER SB, COHEN RD: Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment. Pharmacol. Ther. (2001) 15:35–44.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, FEDORAK RN, IRVINE EJ et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl. " Med. (2000) 342:1627–1632.
   Google Scholar
• ROSENCRANTZ R, MOON A, RAYNES H, SPIVAK W: Cyclosporine-induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am. Gastroenterol (2001) 96:2778–2782.
   PubMed Web of Science ®Google Scholar
• BRYNSKOV J, FREUND L, RASMUSSEN SN et al: A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl. J. Med. (1989) 321:845–850.
   PubMed Web of Science ®Google Scholar
• BRYNSKOV J, FREUND L, NORBY RSet al: Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand. Gastroenterol. (1991) 26:689–695.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, TREMAINE WJ: Cyclosporine treatment of inflammatory bowel disease. Mayo Clin. Proc. (1992) 67:981–990.
   PubMed Web of Science ®Google Scholar
• EGAN LJ, SANDBORN WJ, TREMAINE WJ: Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am.j Gastroenterol (1998) 93:442–448.
   PubMed Web of Science ®Google Scholar
• NICHOLLS S, DOMIZIO P, WILLIAMS CB et al.: Cyclosporin as initial treatment for Crohn's disease. Arch. Dis. Child. (1994) 71:243–247.
   PubMed Web of Science ®Google Scholar
• MAHDI G, ISRAEL DM, HASSALL E: Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am. J. Gastroenterol (1996) 91:1355-1359. loz. RAMAKRISHNA J, LANGHANS N, CALENDA K, GRAND RJ, VERHAVE M: Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease.' Pediatr. Gastroenterol Nutr. (1996) 22:296–302.
   Google Scholar
• BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. Pediatr. (2000) 137:794–799.
   Web of Science ®Google Scholar
• FELLERMANN K, LUDWIG D, STAHL M, DAVID-WALEK T, STANGE EF: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. Gastroenterol (1998) 93:1860–1866.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND L, SINGLETON J, SESSIONS J et al.: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut (1991) 32:1071–1075.
   PubMed Web of Science ®Google Scholar
• URSING B, ALM T, BARANY F et al: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology (1982) 83:550–562.
   PubMed Web of Science ®Google Scholar
• DUFFY LF, DAUM F, FISHER SE et al: Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology (1985) 88:681–684.
   PubMed Web of Science ®Google Scholar
• PRANTERA C, ZANNONI F, SCRIBANO ML et al.: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol (1996) 91:328-332. los. LEIPER K, MORRIS Al, RHODES JM: Open label trial of oral clarithromycin in active Crohn's disease. Aliment. Pharmacol Ther. (2000) 14:801–806.
   Google Scholar
• ARNOLD GL, BEAVES MR, PRYJDUN VO, MOOK WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel. Dis. (2002) 8:10–15.
   PubMed Web of Science ®Google Scholar
• BORGAONKAR MR, MACINTOSH DG, FARDY JM: A meta-analysis of antimycobacterial therapy for Crohn's disease. Am.j Gastroenterol (2000) 95:725–729.
   PubMed Web of Science ®Google Scholar
• MURCH SH, BRAEGGER CP, WALKER-SMITH JA, MACDONALD TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 34:1705–1709.
   PubMed Web of Science ®Google Scholar
• DERKX B, TAMINIAU J, RADEMA S et al.: Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet (1993) 342:173–174.
   PubMed Web of Science ®Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJ, HOMMES DW et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. Med. (1997) 337:1029–1035.
   Google Scholar
• RUTGEERTS P, D'HAENS G, TARGAN S et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761–769.
   Google Scholar
• D'HAENS G, VAN DEVENTER S, VAN HOGEZAND R et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology (1999) 116:1029–1034.
   Google Scholar
• BAERT FJ, D'HAENS GR, PEETERS M et al.: Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology (1999) 116:22–28.
   Google Scholar
• HYAMS JS, MARKOWITZ J, WYLLIE R: Use of infliximab in the treatment of Crohn's disease in children and adolescents. Pediatr. (2000) 137:192–196.
   Web of Science ®Google Scholar
• KUGATHASAN S, WERLIN SL, MARTINEZ A et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. Gastroenterol (2000) 95:3189–3194.
   PubMed Web of Science ®Google Scholar
• BLAM ME, STEIN RB, LICHTENSTEIN GR: Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. Gastroenterol (2001) 96:1977–1997.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE RP et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Eng/. J. Med. (2001) 345:1098–1104.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088–1094.
   PubMed Web of Science ®Google Scholar
• VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT et al: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 117:1278–1287.
   PubMed Web of Science ®Google Scholar
• EHRENPREIS ED, KANE SV, COHEN LB, COHEN RD, HANAUER SB: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271–1277.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, BOWEN-YACYSHYN MB, JEWELL L et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133–1142.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, NIKOLAUS S, MALCHOW H et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 120:1339–1346.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119:1461–1472.
   Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119:1473–1482.
   Google Scholar
• NEURATH ME WANITSCHKE R, PETERS M et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut (1999) 44:625–628.
   PubMed Web of Science ®Google Scholar
• SANDS BE, BANKS, SNINSKY CA et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 117:58–64.
   PubMed Web of Science ®Google Scholar
• GORDON FH, LAI CW, HAMILTON MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology (2001) 121:268–274.
   PubMed Web of Science ®Google Scholar
• HOMMES D, VAN DEN BB, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122:7–14.
   PubMed Web of Science ®Google Scholar
• MCLAIN BI, DAVIDSON PM, STOKES KB, BEASLEY SW: Growth after gut resection for Crohn's disease. Arch. Dis. Child. (1990) 65:760–762.
   PubMed Web of Science ®Google Scholar
• BESNARD M, JABY 0, MOUGENOT JF et al.: Postoperative outcome of Crohn's disease in 30 children. Gut (1998) 43:634–638.
   Google Scholar
• DECKER GA, LOFTUS EV JR, PASHA TM, TREMAINE WJ, SANDBORN WJ: Crohn's disease of the esophagus: clinical features and outcomes. Inflamm. Bowel. Dis. (2001) 7:113–119.
   PubMed Web of Science ®Google Scholar
• CASSON DH, ELTUMI M, TOMLIN S, WALKER-SMITH JA, MURCH SH: Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut (2000) 47:436–440.
   PubMed Web of Science ®Google Scholar
• TOLIA V: Perianal Crohn's disease in children and adolescents. Am. J. Gastroenterol (1996) 91:922–926.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN LH, FRANK MS, BRANDT LJ, BOLEY SJ: Healing of perineal Crohn's disease with metronidazole. Gastroenterology (1980) 79:357–365.
   PubMed Web of Science ®Google Scholar
• LOWRY PW, WEAVER AL, TREMAINE WJ, SANDBORN WJ: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm. Bowel. Dis. (1999) 5:239-245. Website
   Google Scholar
• http://www.nice.org.uk/pdf/ NiceCROHNS40GUIDANCE.pdf Affiliation A Ronald F Bremner MB ChB MRCPCHlt & R Mark Beattie MBBS BSc FRCPCH MRCP2 -rAuthor for correspondence
   Google Scholar
• Division of Infection Inflammation & Repair, School of Medicine, University of Southampton, Southampton, UK E-mail: [email protected]
   Google Scholar
• Paediatric Medical Unit, Southampton General Hospital, Tremona Road, Southampton, S016 6YD, UK Tel: +44 (0)238 079 6888; Fax: +44 (0)238 079 8688; E-mail: [email protected]
   Google Scholar